S
SheMed
Personalised GLP-1 weight management platform for women
About SheMed
The women's metabolic health brand. SheMed offers the UK's first clinician-led GLP-1 medical weight loss programme, alongside blood tests for women, with prescribing and dispensing through CQC-registered eMed and GPhC-registered pharmacy partner eMed Healthcare UK Limited. Personalised, evidence-based care, women-focused throughout. Trusted by 100,000 members.
Read full description
In 2025, the company raised a $50 million Series A, reaching unicorn status as the second UK femtech unicorn after Flo Health. The funding supports UK operations, clinical research, and expansion of its medical and technology teams. Sister brand HeMed extends the same clinician-led model to men.
At a glance
- Founded
- 2024
- Headquarters
- London, United Kingdom
- Sector
- Health Tech & Medtech
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about SheMed on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SheMed on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.